Quinoline derivative
AssigneeOno Pharmaceutical Co., Ltd.
InventorsTakayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro
Life of this patent
Estimating the term…
Abstract
A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases
Claims10
A method for treating an Axl-related disease, the method comprising administering an effective amount of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, or a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, to a mammal in need thereof.
A method for treating an Axl-related disease, the method comprising administering an effective amount of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide or a salt thereof, to a mammal in need thereof.
Dependencies are inferred from the claim text.